Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BIIB113
- Development stage
- Discontinued
- Lead developer
- Biogen
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BIIB113 is an investigational small molecule drug developed by Biogen for the treatment of Alzheimer's disease. It acts as a selective inhibitor of O-GlcNAcase (OGA), an enzyme involved in the removal of O-linked N-acetylglucosamine from proteins. By inhibiting OGA, BIIB113 is intended to reduce the formation of neurofibrillary tangles composed of hyperphosphorylated tau protein—a hallmark pathology in Alzheimer's disease—potentially slowing disease progression. The drug has been evaluated in Phase 1 clinical trials to assess its safety, pharmacokinetics, and target engagement (OGA occupancy) in healthy volunteers and elderly participants[1][2][3][4][5][7].
02
Targets
OGA (Protein O-GlcNAcase)
Beyond the preview
Go deeper on BIIB113.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BIIB113.